Read More

Lucid Diagnostics Announces Peer-Reviewed Publication Of Results From Three Clinical Utility Studies; Studies Demonstrate Real-World Clinical Utility Of EsoGuard Testing To Detect Esophageal Precancer

 Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (NASDAQ:PAVM, PAVMZ)))) ( "PAVmed"),

LUCD

Read More

Bionano Laboratories Announces Publication Of The Analytical Validation Of Its OGM-Based Laboratory Developed Test For Hematological Malignancies And Additional Multi-Site Technical Evaluation Of OGM

Bionano Laboratories today announced the publication of a study covering the analytical validation of its laboratory developed test (LDT), marketed as OGM-Dx™ HemeOne. This LDT is based on optical genome mapping

BNGO